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ABSTRACT
Azacitidine (Aza) is first-line treatment for patients with high-risk myelodysplastic 
syndromes (MDS), although its precise mechanism of action is unknown. We performed 
the first study to globally evaluate the epigenetic effects of Aza on MDS bone marrow 
progenitor cells assessing gene expression (RNA seq), DNA methylation (Illumina 
450k) and the histone modifications H3K18ac and H3K9me3 (ChIP seq). Aza induced 
a general increase in gene expression with 924 significantly upregulated genes but this 
increase showed no correlation with changes in DNA methylation or H3K18ac, and only 
a weak association with changes in H3K9me3. Interestingly, we observed activation 
of transcripts containing 15 endogenous retroviruses (ERVs) confirming previous cell 
line studies. DNA methylation decreased moderately in 99% of all genes, with a median 
β-value reduction of 0.018; the most pronounced effects seen in heterochromatin. Aza-
induced hypomethylation correlated significantly with change in H3K9me3. The pattern 
of H3K18ac and H3K9me3 displayed large differences between patients and healthy 
controls without any consistent pattern induced by Aza. We conclude that the marked 
induction of gene expression only partly could be explained by epigenetic changes, and 
propose that activation of ERVs may contribute to the clinical effects of Aza in MDS.
INTRODUCTION
Myelodysplastic syndromes (MDS) constitute a 
group of clonal, heterogeneous bone marrow diseases 
characterized by disturbed myeloid differentiation 
and a propensity for clonal evolution and leukemic 
transformation. Recurrent mutations in genes encoding 
e.g. epigenetic regulation, splicing and signaling are 
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essential in the pathogenesis of MDS and may contribute 
to the aberrant expression profiles described in the 
disease [1–4]. However, it has since long been widely 
assumed that the aberrant expression profiles and defect 
differentiation in MDS and in leukemic progression are 
closely related to the marked DNA promoter methylation 
reported in several studies [4–7].
Azacitidine (Aza) is a cytosine analog and 
an inhibitor of DNA methyl transferase (DNMT) 
licensed in Europe as first-line treatment for higher-risk 
myelodysplastic syndromes, in the US for all types of MDS 
and frequently used also in other myeloid malignancies, 
such as acute myeloid [8, 9] Treatment has been confidently 
associated with prolonged survival in these patient groups 
[10]. Aza treatment results in reduced DNA methylation 
as demonstrated by several studies in vivo and in vitro, 
although the degree of demethylation seems to be limited 
[4, 11–15]. A plethora of in vitro studies have investigated 
the in vitro effects of Aza, however, only a limited number 
of these have used primary MDS cells in the experiments 
[16]. In a previous study we observed a demethylating 
effect of Aza on primary MDS progenitors, and a reduction 
in H3K9ac and H3K27ac, reflecting a more complex 
effect of Aza on the epigenome than previously believed 
[4]. Other studies have investigated methylation status 
in patient bone marrow before and after Aza treatment. 
Some of these demonstrated a prognostic beneficial effect 
of an initial reduction in DNA methylation, but whether 
this reflects a causative effect or only an association is 
unclear [12, 13, 17–19]. A couple of studies have shown 
an association between pre-treatment DNA methylation 
profiles and response, while others find no such association 
[13, 20–22]. It is important to note that these studies most 
commonly evaluate promoter methylation, and do not take 
into account changes in methylation outside the promoters. 
Thus, in order to predict which patients will respond to Aza 
it is vital to understand its mechanism of action on primary 
MDS cells.
The link between DNA methylation and transcription 
as a basic biological principle is well established, although 
promoter DNA methylation does not always correlate to 
gene expression. In fact, in AML, there is only a moderate 
correlation between DNA methylation and transcription 
[23–25]. There is hitherto no clear evidence that changes 
in gene expression observed during Aza treatment results 
from changes in DNA methylation. A few studies have 
investigated the genome-wide effects of Aza treatment in 
vitro on DNA methylation and gene expression in various 
cell lines. In HEK 293 cells, only a small minority of genes 
upregulated by Aza could be explained by changes in DNA 
methylation, and vice versa in hypermethylated colon 
cancer cells; only 1,6% of genes demethylated by Aza 
gained chromatin accessibility [26, 27]. Additional studies 
confirm a decrease in DNA methylation by Aza but show 
modest effects on gene expression and a lack of association 
between demethylation and gene expression [28–31].
Two papers from 2015 showed that in solid tumor cell 
lines, Aza induces expression of endogenous retroviruses 
(ERVs), formation of dsDNA and a subsequent activation of 
the innate immune system after long time culture [32, 33].
This is the first study to simultaneously assess the 
global genome-wide effects of Aza on DNA methylation, 
the histone modifications H3K9me3 / H3K18ac, and gene 
expression in MDS bone marrow progenitors in vitro. Aza-
treatment of MDS CD34+ progenitors resulted in a genome-
wide but modest DNA demethylation predominantly in 
heterochromatin, and was accompanied a similar change 
in H3Kme3. In line with what has previously been 
demonstrated in cell lines, we observe an activation of 
ERVs in these primary MDS progenitors. Furthermore, 
we showed that Aza induces a general increase in gene 
expression, although only to a minor extent explained by 
epigenetic changes, however partially explained by an 
increase in transcription factors affecting differentiation.
RESULTS
Patient population
Bone marrow samples were collected from 11 
patients with a clinical indication for Aza treatment; 
(6 higher-risk MDS, 4 AML with multilinear dysplasia and 
20–29% blasts and 1 CMML-2). Patient characteristics are 
shown in Table 1. One patient sample did not yield enough 
cells for further experiments (data not shown), and ten 
patient samples thus proceeded to the culture experiments. 
All samples were used fresh without a previous freezing / 
thawing procedure. Analyses on DNA methylation, gene 
expression H3K9me3 and H3K18ac was successful in 9, 
4, 6 and 2 patients, respectively.
Cell culture growth and viability
Aza moderately decreased cell growth in the 
cultures compared to cells cultured without Aza; median 
cell growth for Aza treated samples at 24 h was 140% 
(range 65-333%) compared to control samples (196%, 
range 87-390%), thus there was no significant change in 
cell growth upon Aza treatment (Supplementary Figure 1). 
At continued culture up to 48 hours, without additional 
Aza, both control and Aza treated cells discontinued 
growing and started dying, and cell count was 129% 
(range 100-283%) of baseline for control and 98% (range 
86-318%) of control for Aza treated cells.
Correlation between gene expression and 
epigenetic marks in untreated cells
We observed an inverse correlation between 
DNA methylation and gene expression (rho -0.305, 
p=9.6×10-197; Spearman’s rank test), showing a significant 
correlation between gene-specific DNA methylation and 
gene expression in MDS CD34+ cells. Additionally, DNA 
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methylation correlated significantly to the active chromatin 
mark H3K18ac with an inverse correlation (rho -0.318, 
p<10-200), and to the repressive chromatin mark H3K9me3 
(rho 0.144, p=4.5×E-80) indicating that DNA methylation 
and chromatin marks interplay to regulate gene expression, 
and that genes with closed chromatin also are highly DNA 
methylated. Active H3K18ac and repressive H3K9me3 
chromatin marks also correlate inversely to each other (rho 
-0.152, p=3×10-174). In addition, there was a correlation, 
although less pronounced, between chromatin marks and 
gene expression (rho -0.06, p=6×10-9 for H3K9me3; and 
rho 0.083, p=3.5×10-16 for H3K18ac).
Increased gene expression after Aza exposure
Comparison of cells cultured without Aza for 
24 h vs. 48 h (paired samples from 2 patients), showed 
no global changes in gene expression, with 5011 and 
4135 genes being up and down regulated, respectively, 
indicating that the culture conditions per se did not 
influence the results (Figure 1A).
Comparing treated and untreated cells cultured for 
24 h (paired samples from four patients), we observed 
a general increase in global gene expression among the 
Aza samples, with 7444 and 2930 genes up and down 
regulated, respectively; whereof 924 and 54 with p-value 
<0.05, (Figure 1A and 1D). The median fold change 
was 1.61 (q1=1.16; q3=3.32). Global gene expression 
increased in all four patients (data not shown).
Cells cultured with Aza for 24h, followed by another 
24 hours in culture without Aza showed a general decrease 
in gene expression between 24 and 48h, with 2038 and 
7336 genes up and downregulated, respectively (Figure 
1B). Out of the genes 7444 genes upregulated in the 24h 
Aza samples, 5952 (80%) genes had decreased expression 
in the 48h Aza samples, indicating a rebound effect. 
Similarly, out of the 2930 genes downregulated in the 24h 
Aza samples, 949 (32%) showed increased expression in 
the 48h Aza samples. GO analysis of upregulated genes 
at 24 h Aza culture showed enrichment of genes involved 
in translation, RNA processing and ribosomal function 
(Supplementary Table 2).
Table 1: Patient characteristics
Patient 
identity
WHO Marrow 
blast 
count
Cellularity Hb WBC ANC Plt Transfusion 
dependency
Cytogenetics IPSS Mutations Treatment Response
1 RAEB-II 11 70 89 1.1 0,2 99 Yes Normal Int-2 TP53 Intensive 
chemotherapy
Complete 
remission
2 RAEB-I 6 70 104 2.9 1.4 69 Yes Complex High DNMT3A; 
SF3B1; 
TET2
Supportive 
care
Never 
evaluated
3 RCMD 3 90 91 3.7 2 92 Yes Complex Int-2 No mutation Azacitidine + 
Lenalidomide
Complete 
remission
4 RAEB-II 10 50 95 2.2 0.8 103 No Del5q Int-2 No mutation Azacitidine Never 
evaluated
5 AML w 
multilinear 
dysplasia
28 80 110 2.3 0.9 43 No Complex High IDH1;TET2; Azacitidine Complete 
remission
6 AML w 
multilinear 
dysplasia
17 80 83 10.4 2.9 255 Yes Normal High RUNX1; Azacitidine Progression
7 AML w 
multilinear 
dysplasia
23 80 130 1.8 0.5 85 No Normal High No mutation Azacitidine Complete 
remission
8 CMML 14 100 104 49.1 31.8 11 Yes Normal NA ASXL1;KR
AS;PRPF40
B;RUNX1;
U2AF1;
Azacitidine marrow 
Complete 
remission
9 RAEB-I 9 30 111 1.6 0.4 196 Yes Complex Int-2 TP53;TP53; Azacitidine Stable disease
10 RAEB-II 14 80 93 2.4 0.4 63 Yes -Y Int-2 SRSF2; 
TET2;TET2
Azacitidine Hematological 
improvment
11 AML w 
multilinear 
dysplasia
28 60 100 4,1 1,2 86 No Complex High CREBBP; 
MLL; 
NRAS
Intensive 
chemotherapy
Stable disease
Abbreviations: RAEB-II Refractory anemia with excess of blasts. RCMD refractory cytopenia with multilinear dysplasia, AML acute myeloid leukemia, 
CMML chronic myelomonocytic leukemia, WBC white blood cell count, ANC absolute neutrophil count, IPSS international prognostic score system
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Figure 1: Effects of Aza on gene expression. (A) Differences between Aza 24h culture vs. control 24h culture (B) Aza 48h vs. Aza 
24h (C) Control 48h vs. control 24h. (D) Change in gene expression; all genes sorted from most negatively to most positively changed and 
printed as a barplot. (E) Unsupervised clustering of gene expression data.
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Samples clustered together mainly based on patient 
identity, and not based on whether treated with Aza or not 
(Figure 1E).
Aza induces a general but limited DNA 
demethylation
DNA obtained from CD34+ bone marrow 
cells allowed for assessment of differences in global 
methylation between samples cultured with or without Aza 
for 24 h (n=9), freshly isolated samples and cells cultured 
without treatment for 24 h (n=4), samples cultured without 
treatment for 48 h (n=2) and samples cultured with Aza 
for 24 h or 48 h (n=4). The density plot in Supplementary 
Figure 2 reveals an even distribution of β-values across 
the samples.
No effect of the cell culture condition on global 
DNA methylation pattern was identified in the untreated 
cultures at 0 h and 24 h, indicating that culture conditions 
per se did not alter methylation status (Figure 2D), despite 
the fact that cells were proliferating, see Supplementary 
Figure 1.
We identified 65 769 differentially methylated 
probes (DMPs) comparing samples cultured with or 
without Aza for 24h; the vast majority of these (n=65 664) 
were less methylated in the Aza treated samples (Figure 
2A). The relative proportion of DMPs was lower in CpG 
islands compared to the Illumina 450k reference while 
the proportion was higher for open sea probes (Figure 
2G). Similarly, the proportion of DMPs compared to the 
reference was smaller for probes located in proximity 
to transcription start sites while it was higher for probes 
located in gene bodies or non-gene related probes, (Figure 
2G). Moreover, comparing the DMP proportion in relation 
to the epigenome roadmap of primary CD34+ cells, we 
observed an enrichment of DMPs in heterochromatin 
defined by H3K9 methylation in our material (Figure 2G) 
[34]. The relative median change in β-value per probe, 
comparing Aza- and control samples, was -0.018 (q1=-
0.035; q3=-0.007) while the relative change per gene, 
calculated as mean change for all probes annotated to 
specific genes, was -0.018 (q1=-0.026; q3=-0.012), thus a 
very modest reduction (Figure 2E). In total, 20124 and 148 
genes showed decreased and increased DNA methylation, 
respectively. When looking only at promoter-associated 
probes (TSS-1500bp), the median relative change per 
gene was β -0.015. All patients except one showed a 
global decrease in DNA methylation; see patient-specific 
effects in Supplementary Figure 3. We then calculated the 
degree of DNA demethylation on our previously published 
dataset which was generated using the same methodology 
[4]. Indeed, the degree of DNA demethylation was very 
modest and at the same levels as in the present study 
with a mean decrease in β -value of 0.024 and 0.012 in 
MDS CD34+ cells and healthy control CD34+ cells, 
respectively.
The 48 h Aza samples showed a general increase in 
methylation compared to the 24h Aza samples, although 
no significant DMPs were identified (Figure 2B). Whether 
this reflects changes at the single cell level or changes 
in cell composition due to proliferation remains to be 
investigated. The total effect of Aza over 48h, comparing 
48h Aza samples with 48h untreated samples was a global 
reduction in DNA methylation (Figure 2C).
An unsupervised clustering analysis showed 
strong clustering based on patient identity rather than on 
treatment or culture conditions (Figure 2F). We could 
not find any clustering according to mutation pattern, 
cytogenetics, blast count, diagnosis or clinical treatment 
response (data not shown).
To assess whether DNA demethylation was more 
profound in the CD34- compared to the CD34+ progenitor 
fraction, vital frozen MNC from five MDS patients were 
cultured for 24h with or without Aza, then separated into 
CD34+ and – fractions and assessed for DNA methylation 
with the Illumina 450k array. The CD34- cells were 
however even less demethylated than CD34+ cells from 
the same experiment (change in β value of -0.008 vs 
-0.027), which contradicts the potential explanation that 
Aza improves the hematological condition mainly by 
acting on more mature precursor cells, see Supplementary 
Figure 4, 5 and 6.
Changes in active chromatin mark H3K18ac
Analysis of H3K18ac, comparing cells cultured for 
24h with or without Aza, was successful with more than 
10 million reads in 2 patients. The median fold change 
between Aza and control samples for peaks of H3K18ac 
after peak calling was 1.01 (q1=0.95; q3=1.07), as shown 
in Figure 3A. There was avariation in H3K18ac pattern 
between the two untreated samples, differences that 
remained in the Aza samples, and normal CD34+ cells 
clustered separate from MDS CD34+ cells with regard 
to H3K18ac pattern (Figure 3C). A significant difference 
between normal CD34+ and MDS CD34+ cells was found 
in 1203 genes, with mean number of reads = 94. No GO 
pathways were significantly enriched.
Changes in repressive mark H3K9me3
Analysis of H3K9me3 patterns, comparing cells 
cultured for 24h with or without Aza, was successful 
with more than 10 million reads per sample in 6 patients. 
Median fold change between Aza and control samples for 
peaks of H3K9me3 after peak calling was 1.09 (q1=0.71; 
q3=1.67), see Figure 3B. Similar to the patterns for 
H3K18ac, healthy CD34+ cells clustered separately from 
MDS patients samples with regard to H3K9me3 pattern 
(Figure 3D).
Included genes in the heat map were 504 genes with 
a significant difference between normal CD34+ and MDS 
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Figure 2: Effects of Aza on DNA methylation. (A) Volcano plot illustrating differences between Aza 24h vs control 24h. (B) Aza 48h 
vs 24h (C) Aza 48h vs control 48h (D) Control 24h vs no culture (E) Mean change in methylation for all probes annotated for specific genes; 
all genes sorted from most negatively to most positively changed and printed as a barplot. (F) Unsupervised clustering of methylation data 
(G) Log fraction of differentially methylated probes (DMPs) divided by non-DMPs in different areas of the genome ass annotated by the 
Illumina 450k array (relation to CpG island and promoter) and epigenomic roadmap (heterochromatin).
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CD34+, with a mean number of reads of 28. Unsupervised 
clustering of H3K9me3 data showed clustering mainly 
based on patient identity (Figure 3D).
No GO pathways were significantly enriched.
Correlation between change in epigenetic marks 
and gene expression
There was a highly significant correlation between 
changes in the repressive chromatin mark H3K9me3 and 
changes in DNA methylation (rho 0.136, p= 1.7x10-69). 
Interestingly, by analyzing patientwise correlation (n=6), 
we observed a strong correlation reflected in very low 
p-values for each patient, see Supplementary Table 3. 
Interestingly three patients each showed a positive and a 
negative correlation, respectively, without any association 
disease characteristics e.g. cytogenetics, morphology 
or mutational status (data not shown). Moreover, we 
observe a weak correlation between H3K9me3 and gene 
expression (rho 0.053, p=2.38x10-7) which only can 
explain a minor part of the gene expression variation. No 
other epigenetic marks correlated with gene expression or 
with another epigenetic mark (H3K9me3 and H3K18ac).
Motif analysis
Analysis of common transcription factor binding 
motifs in the 924 significantly upregulated genes in the 
Aza samples compared to non-treated samples showed 
enrichment of binding motifs for eight transcription 
factors that were themselves upregulated more than 1.8-
fold (median), namely ELK1, STAT 1, STAT3, RUNX1, 
GABPA, ERG, NRF1 and PU.1. Several of these 
transcription factors regulate differentiation, indicating 
that Aza indeed may affect hematopoietic stem/progenitor 
cell differentiation. Interestingly, the active chromatin 
mark H3K18ac was already high in these genes and 
did not increase in the Aza treated samples. Neither did 
DNA methylation change significantly in any of the 
genes encoding for those transcription factors (median 
reduction of β-value of 0.011). Hence, changes in 
epigenetic regulation, as measured by H3K18ac and DNA 
Figure 3: Effects of Aza on histone modifications. (A) Change in H3K18ac; all genes sorted from most negatively to most positively 
changed and printed as a barplot (B) Change in H3K9me3c (C) Heat map and clustering of patients based on H3K18ac (D) Heat map and 
clustering of patients based on H3K9me3.
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methylation, cannot explain the increased expression of 
the TF, and the upstream regulation remains unknown.
Aza induces expression of transcripts containing 
ERV-like repetitive elements
By overlapping gene expression data with regions 
annotated as repetitive elements, we observed 16 TFEs 
overlapping with repetitive elements, being significantly 
(p<0.05) upregulated in the Aza treated samples, while 
only three were significantly downregulated. Of the 
upregulated repetitive elements, 15 belong to the ERV 
family (Supplementary Table 4 and Supplementary Figure 
7). No Illumina 450k probes were annotated to the ERV-
associated regions and the change in DNA methylation 
in these regions could therefore not be analyzed. We 
observe no general reduction of H3K9me3 peaks in the 
Aza samples compared to control samples over the ERV 
regions (data not shown).
DISCUSSION
To better understand the effect of Aza on epigenetic 
marks and transcription profiles in MDS progenitors, we 
set out to assess changes in DNA methylation, chromatin 
marks and gene expression in primary MDS patient 
CD34+ cells, after short term incubation with Aza. The 
initial hypothesis was that promoter DNA demethylation 
would lead to gene expression, but that an increase in 
repressive chromatin marks may counteract this process 
[4]. Indeed, we found a significant increase in global 
transcription levels in all patients after 24 h Aza exposure. 
Upregulated genes were mainly involved in GO pathways 
including translation, RNA processing and ribosomal 
function. As expected, we detected a general, significant 
DNA demethylation following Aza treatment, however, 
the degree of demethylation in each specific gene was 
very modest, with a mean reduction of β-value of only 
0.018, and thus of questionable biological relevance. The 
DNA demethylation occurred in all genomic regions, 
but to a larger extent in non-promoter regions, open-sea 
and in regions annotated as heterochromatin, supporting 
the interpretation that this was not the direct cause of 
increased gene expression. This was also supported by 
the lack of correlation between changes in expression and 
DNA methylation at the individual gene level.
We next searched for other epigenetic explanations 
for changes in gene expression and assessed if Aza 
treatment affected active (H3K18ac) or repressive 
(H3K9me3) chromatin marks, and found that changes 
induced by Aza in H3K9me3, which is strongly associated 
with heterochromatin formation, exhibited a weak 
correlation to the Aza induced global changes in gene 
expression while H3K18ac showed no such correlation 
with change in gene expression. Moreover, we observed 
a strong correlation between change DNA demethylation 
and change in H3K9me3, indicating that Aza may have 
a profound effect in heterochromatin regions, defined by 
H3K9me3 enrichment. The reason for the paradoxical 
observation of three patients with positive, and three 
with negative correlation between DNA demethylation 
and change in H3K9me3 is unclear. Hypothetically, 
differences in epigenetic baseline pattern and mutational 
status of histone modificating enzymes might explain the 
differences. In line with these observations, a previous 
publication reports different Aza-induced effects on histone 
modificaitons depending on what type of cell line is used, 
indicating that different cells might respond epigenetically 
different to Aza [35]. There was a tight correlation between 
epigenetic marks defining heterochromatin e.g. DNA 
methylation and H3K9me3 in the untreated samples. 
Additionally, there was a significant baseline correlation 
between all epigenetic modalities and gene expression, 
indicating high quality and robustness of our data.
As the marked induction of gene expression 
only could partly be explained by epigenetic changes, 
we analyzed TF binding motifs of the significantly 
upregulated genes, and found eight transcription factors 
significantly enriched for binding sites in these genes, 
all of which were themselves upregulated in expression. 
Thus, at least part of the upregulated genes may be 
explained by Aza-induced increase of the above TFs. 
Since several of them have important regulatory functions 
in hematopoietic differentiation, interference with the 
differentiation process might be part of how Aza exerts its 
effect. Our epigenetic data cannot, however, explain the 
change in expression of these TF and the upstream events 
remain to be further investigated.
Interestingly, we observed an activation of 15 ERVs 
in the Aza treated samples. Recent publications in cell 
lines have demonstrated an early Aza-induced activation 
of ERVs, followed by a later activation of immune 
response genes [32, 36]. We show for the first time that 
Aza treatment results in ERV activation also in primary 
CD34+ MDS cells. The short incubation time in our 
experiment did not, however, allow us to study delayed 
upregulation of immune response genes, as long-term 
incubation of primary CD34+ MDS cells is not possible 
due to cell differentiation and reduced viability beyond 48 
hours of culture [4]. Although we have not analyzed DNA 
methylation over these repetitive elements, activation is 
consistent with the documented role for DNA methylation 
in silencing of retrotransposons in mouse embryonic 
stem cells [37]. It is well established that global DNA 
demethylation during mammalian gametogenesis and 
early embryonic development results in the de-repression 
of ERVs and this correlates with the pluripotent capacity 
[38, 39], and differential ERV expression is involved in 
embryonal cell differentiation [40] Thus it is possible that 
the increased expression of ERVs we observe in MDS 
cells could contribute to changes in cell differentiation 
upon treatment with Aza.
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In contrast to previous studies on cell lines and 
primary AML cells, we detected a general increase in 
polyadenylated RNA induced by Aza, as assessed by 
RNA sequencing. One possible explanation for this novel 
observation compared to other studies on non-MDS 
cells is that MDS progenitors might be more susceptible 
to Aza. Another is that the spike-in normalization RNA 
sequencing method used in our study might yield higher 
sensitivity compared to the array-based gene expression 
methods used in other studies. Primarily, we propose 
that the increased mRNA levels are due to increased 
transcription. However, although previous studies indicate 
that Aza leads to reduced stability of RNA and increased 
degradation [41–43], we cannot exclude the possibility of 
decreased degradation of mRNA.
The current study is the first to comprehensively 
investigate the associations between epigenetic modalities 
and gene expression in Aza-treated primary MDS bone 
marrow cells. We demonstrate a complex effect of Aza 
on the epigenome and the transcriptome which gives 
important information in the search for how Aza exerts 
its effect. However, the link between the epigenetic 
modalities and gene expression is only partly explained in 
our study and further studies mapping other histone marks, 
and also mapping DNA methylation using methods with 
higher resolution e.g. bisulphite sequencing are warranted. 
The role of the TFs and ERVs identified as activated in our 
study needs to be studied further in functional assays as 
well as in an in vivo setting.
METHODS
Patient population
Bone marrow samples from consecutive patients 
with an indication for Aza treatment, i.e. MDS 
with International Prognostic Score System (IPSS) 
intermediate-2 or high, Chronic myelomonocytic leukemia 
(CMML) with >10% blasts or Acute myeloid Leukemia 
(AML) with multilinear dysplasia and <30% blasts, were 
collected [44]. All patients were treated in clinical routine 
practice at the Karolinska University Hospital. Samples 
proceeded to cell culture without preceding freezing / 
thawing. The study was approved by the Ethical committee 
(Dnr 2010/427-31/1) at Karolinska Institutet, Sweden.
Cell culture
Fresh mononuclear bone marrow cells were 
isolated with Lymphoprep® according to manufacturer’s 
instructions, and separation of CD34+ progenitor cells 
was done with MACS® Microbeads technology. Cells 
were cultured with and without 1µM Aza (Celgene, New 
Jersey, US) in Erythroblast medium (containing Isocove’s 
medium, BIT (15%), Rh SCF (25 ng/ml), Rh IL-3 (10 ng/
ml), Rh IL-6 (10 ng/ml) and L-Glut 200 mm (1%)) in a 
humidified incubator with an atmosphere of 5% CO2 at 
37°C, as previously described [4]. Aza was added at the 
start of the culture experiment. The cells were harvested 
at 0 h after separation, and after 24h and 48 h with and 
without exposure to Aza. Cells continuing to 48 h of 
culture were washed at 24 hours and then cultured in 
medium for another 24 h without addition of Aza. The 
cells were counted in a Neuberger chamber using Trypan 
blue (dilution 1:20). Cells were collected and centrifuged 
at 1500 rpm for 10 min. The supernatant was discarded 
and the pellet was then used for further applications. Cell 
growth was assessed by counting the number of cells 
present in the culture, calculating the relative difference 
of live cells at harvest compared to the amount of cells at 
time 0 h. Moreover, in a second independent experiment, 
vital frozen MNCs from five higher-risk MDS patients 
(of which two were the same patients as included in the 
culture experiment of primary fresh CD34+ cells) were 
thawed, ficoll separated and cultured for 24h with or 
without Aza (1 µM), where after CD34+ and CD34– cells 
were separated by magnetic beads as described above
DNA/RNA extraction
Genomic DNA and RNA from CD34+ cells was 
extracted using the Allprep® kit, following manufacturer’s 
instructions (Allprep DNA/RNA/Protein kit, Qiagen, 
Valencia, US). The concentration was measured with the 
Qubit® Assay based method (Thermo Fischer Scientific, 
Waltham, US).
Mutational analyses
Eleven patients were analyzed for 42 genes 
recurrently mutated in myeloid disorders using Haloplex® 
target enrichment technology (Agilent Technologies, CA, 
US) followed by high throughput sequencing as previously 
described (Supplementary Table 1) [45].
Methylation profiling
Bisulfite modified DNA from bone marrow CD34+ 
cells, separated and extracted according to the above, was 
processed using Illumina-supplied reagents and conditions 
and run on Illumina 450k bead chip arrays at the BEA 
core facility, Karolinska Institutet. Pre-processing and 
normalization used a pipeline reported previously [46] 
DNA methylation levels β (1 = fully methylated, 0 = 
fully demethylated) and M were defined as described [46, 
47]. Briefly, the R packages lumi, methylumi, minfi and 
limma were used for quality control, normalization, and 
differential methylation analysis [47–50]. We filtered-out 
the following: 65 probes overlapping known SNPs in their 
sequence (allele frequency >1% in European population), 
probes on chromosomes X and Y and probes with a 
detection p value >0.01 exceeding 5% of the samples. 
Color-bias adjustment and quantile normalization were 
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performed on pooled signal intensities, as implemented in 
lumi [47]. We then performed probe type bias adjustment 
using BMIQ normalization on β-values [51]. Differentially 
methylated probes (DMPs) were defined using limma 
on M-values, including the treatment (Aza vs. Control) 
and the patient as covariates [49]. We selected the 
following contrasts: Aza 24 h vs. control 24 h (effect of 
Aza treatment at 24 h) and control 24 h (effect of tissue 
culture at 24 h). For each contrast, coefficients (difference 
in M-values) p-values and false discovery rate (FDR) were 
estimated using an empirical Bayes method included in 
the limma package. DMP were selected if FDR<0.05. 
Gene-specific methylation for each gene was calculated as 
mean of all probes annotated to specific genes according 
to the Illumina annotation system. Similarly, gene specific 
promoter methylation was calculated including only 
promoter-associated probes.
Standard Illumina annotation was used to annotate 
methylation data, in addition to data on the epigenome 
of primary CD34+ cells, with 15 distinct chromatin 
states as defined by five histone marks (H3K4me3, 
H3K4me1, H3K27me3, H3K36me3, H3K9me3) in the 
Epigenome road map project (https://sites.google.com/
site/anshulkundaje/projects/epigenomeroadmap) [52]. 
For each annotation category, the relative proportions of 
probes located within each feature type were calculated for 
DMPs, non-DMPs and the entire array.
RNA sequencing and bioinformatics
The single cell–tagged reverse transcription (STRT) 
RNA-seq method with modifications was used to measure 
transcription initiation at the 5′end of polyA+ transcripts 
starting from 10 ng of total RNA as template [53, 54]. 
According to the 10 ng bulk RNA input, the cDNA was 
amplified by using 14 cycles of PCR and 10 additional 
cycles to introduce the complete sets of adapters for Illumina 
sequencing (Illumina). The library was size selected 
(200–400 bp) by using sequential Agencourt® AMPure® 
XP magnetic beads (Beckman Coulter, A63881, CA, US) 
selection protocol and 0.7× and 0.22× ratios, respectively. 
Preprocess alignment and differential expression tests were 
performed on UCSC hg19 reference genome by STRTprep 
which was an updated version (v3dev branch; https://github.
com/shka/STRTprep/tree/v3dev) for quantitations by, not 
only protein-coding genes, but also transcript far 5’-ends 
(TFEs) [54, 55]. Overlap between TFEs and repetitive 
elements, which were provided by UCSC genome browser, 
was also examined [56]. Gene ontology (GO) analysis was 
performed using the GOrilla software [57].
Chromatin immunoprecipitation followed by 
sequencing (ChIP seq)
CD34+ cells were treated as described above 
and 250 000 cells per condition were used for ChIP, 
using a 10% of each as Input. Cells were collected by 
centrifugation (5 min, 1600 rpm, 4°C) and resuspended 
in PBS (Invitrogen, city) up to 20 million cells/ml. 
Cells were fixed adding formaldehyde (37%, Sigma 
Aldrich, 252549, NJ, US) to the cell suspension to a 
final concentration of 1% with an incubation of 8 min at 
room temperature. Crosslinking was quenched by adding 
2.5 M glycine to a final concentration of 125 mM, and 
cells were washed twice with ice cold PBS. ChIP was 
performed using the iDeal ChIP-Seq kit set for Histones 
(Diagenode, AB-001-0024, Liege, Belgium ) following the 
manufacturer’s instructions. For chromatin shearing, 300 
µl of cell suspension in shearing buffer were transferred 
to 1.5 ml TPX microtubes (Diagenode, C30010010-300, 
Liege, Belgium), city) and sonicated using the Bioruptor 
sonicator (Diagenode, B01020001). The shearing protocol 
for CD34+ cells was optimized to 25 cycles of sonication 
(30s on, 30s off) with vortex and centrifugation step 
every 10 cycles to produce fragments 200–500 bp. For 
the magnetic immunoprecipitation, 1 μl of ChIP-seq 
grade control antibody was added per tube with 100 μl of 
sheared chromatin. The antibodies used were: H3K9Me3 
(Abcam, ab8988) andH3K18Ac (Abcam, ab1191).
After decrosslinking, the fragmented DNA 
was purified with the MiniElute PCR Purification 
Kit (Qiagen, 28004) and the DNA concentration was 
measured using Qubit Fluorometric Quantitation with 
High Sensitivity (Thermo Fischer Scientific, Waltham, 
US, Q32851). The library was prepared using the 
ThruPLEX DNA-seq Kit with single indexes (Rubicon 
Genomics, Ann Arbor, MI, R400428) following the 
instructions of the manufacturer. The quality of samples 
was subsequently evaluated using the 2100 Bioanalyzer 
system (Agilent, Santa Clara, CA) and the library clean-
up and size selection was performed using AMPure® XP 
magnetic beads (Beckman Coulter). DNA concentration 
was measured using Qubit (Thermo Fischer Scientific, 
Waltham, US, Q32851). Samples were barcoded and up 
to four samples per lane were pooled.
After pooling of libraries, libraries were hybridized 
to the flow cell and sequenced on the Illumina HiSeq2000 
with single end sequencing. As a primary quality control of 
the sequencing the intensities and base calling parameters 
were checked (using default parameter settings) with the 
HiSeq Control software, followed by de-multiplexing of 
the libraries.
Bioinformatic analysis of ChIP sequencing data
The raw sequencing reads in FASTQ format were 
quality checked with the FASTQC tool (Babraham 
Bioinformatics, Cambridge, UK, version 0.11.4). 
Adapter sequences and duplicates were removed. We 
aimed for at least10 million filtered reads. The filtered 
data was then aligned with Bowtie2 (version 2.2.6) to 
the Human Reference Genome Issue HG-19 (https://
Oncotarget28822www.impactjournals.com/oncotarget
www.ncbi.nlm.nih.gov/grc/human/issues/HG-19) with 
the requirement of unique alignment. Bedgraphs were 
generated using BED tools (BEDtool v 2.16.2) and 
data was visualized as custom tracks within the UCSC 
genome browser (https://genome.ucsc.edu). Peak calling 
was performed with HOMER (v4.8, 1-13-2016, http://
homer.salk.edu.homer/) to determine enrichment over 
the input samples across the whole genome. Peak 
size was optimized to 1000 bp, with the minimum 
distance to the next peak set to 2500 bp. The closest 
transcription start site (TSS) was then annotated to 
the enriched regions using HOMER, and differential 
analysis between treated and control samples were 
performed with edgeR (Bioconductor version 3.14.0, 
https://bioconductor.org/packages/release/bioc/html/
edgeR). For analysis of correlation of ChIP seq data to 
RNA seq and DNA methylation data, raw filtered data 
were mapped to the human reference genome as above 
(HG-19, Bowtie2). Thereafter we calculated tags within 
100 000 bp from TSS and annotated this peak to Ref 
Seq (https://www.ncbi.nlm.nih.gov/refseq) to find genes 
in the corresponding positions. Thereafter, differences 
between Aza treated and control sample were assessed 
in EdgeR as fold change, which was used for correlation 
comparison to RNA seq and DNA methylation data.
Motif finding analysis for gene expression data
Promoter transcription factor (TF) binding motif 
analysis was performed for genes with significantly 
increased gene expression at 24 h in Aza samples 
compared to untreated controls, with the Homer Motif 
analysis algorithm (version 4.8, 1-13-2016). The algorithm 
analyzed gene promoters for motifs enriched in our 
target gene promoters relative to known human gene 
promoters. Parameters used for the analysis were the input 
file containing the gene ID of target genes, background 
promote set (HG-19), start and end position relative to the 
transcription start site (-start -400 -end 100 to TSS and 
motif length set to 8, 10 and 12 nucleotides.
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